Treatment Outcomes Among Black Adults Receiving Medication for Opioid Use Disorder

Abstract

Largely due to structural racism, Black people with substance use disorder have worse outcomes than their White counterparts. The opioid epidemic has amplified these racial disparities. Little is known about strengths that buffer against the systemic issues that disproportionately impact Black adults with opioid use disorder (OUD), particularly those receiving buprenorphine for OUD. The objectives of this study are to (1) assess psychosocial and clinical predictors of OUD outcomes and (2) explore differences in OUD outcomes by gender among a sample of Black adults receiving buprenorphine. This is a secondary data analysis of a cross-sectional survey and medical record review with a convenience sample recruited from an addiction medicine clinic. Analyses included Black participants who provided at least one urine drug test during the study period (n = 98). Prospective 6-month OUD outcomes (treatment retention, substance use recurrence, and buprenorphine continuation) were abstracted from the medical record. Univariate analyses explored differences by gender. Multivariate regressions assessed predictors of OUD outcomes. Participants were 53% women and middle-aged (47 ± 12 years). The majority (59%) had been in treatment for at least 1 year at study enrollment. Substance use recurrence was common, but many individuals remained in treatment. OUD outcomes did not differ by gender. Older age and absence of injection opioid use history were significant predictors of treatment retention and buprenorphine continuation. When provided access to high-quality treatment, Black adults with OUD demonstrate positive outcomes. Addressing structural racism and developing culturally informed treatment interventions are necessary to improve access to high-quality care for this community.Keywords Black adults . Opioid use disorder (OUD) . Medication for opioid use disorder (MOUD) . Buprenorphine . Social determinants of health

Patient experiences of COVID-19-induced changes to methadone treatment in a large community-based opioid treatment program in Baltimore

“…Furthermore, racially minoritized and economically disadvantaged people experience less access to treatment (including telehealth) and higher rates of overdose mortality across the United States ( Gold et al, 2020 ; Alexander et al, 2021 ; Centers for Disease Control and Prevention (CDC), 2022 ). It is important to understand experiences of methadone medication delivery among individuals engaged in care at OTPs, especially marginalized populations who experience the greatest barriers to accessing medications, and to use that data to inform policies regarding methadone dispensing ( Mitchell et al, 2013 ; Madras et al, 2020 ; Parlier-Ahmad et al, 2022 ).…”

From describing disparities to understanding why disparities exist: Anti‐racist methods to support dental public health research

“…Examples : Fostering provider values of mutual learning, trust in patients' knowledge and values and consensus building to collaboratively reduce disparities [45–47]…”

Redefining Child Protection

“…4 Structural racism results in racial disparities in substance use disorder (SUD)–related morbidity, mortality, and treatment outcomes through the inequitable burden of mass incarceration; stigma; discrimination affecting access to health care, housing, employment, and income; and systemic barriers to SUD treatment for Black Americans. 5 Structural racism is evident not only in treatment access and SUD clinical outcomes, but also in approaches to assessment of child safety and reporting to child welfare services. Black people and their newborns are more likely to be drug tested in medical settings, and Black newborns are four times more likely than White newborns to be reported to child welfare services at delivery.…”